The FDA issued another round of warning letters to telehealth companies last week, and published them today alongside a warning to telehealth companies. But buried beneath the headlines is a signal that could be more important than the letters themselves: the agency appears to be focusing its fire on marketing practices, not on 503A compounding as a whole.
Alongside the warning letters, the FDA published new guidance detailing what it considers false or misleading promotion of compounded GLP-1 medications. The document reads less like a broadside against compounding and more like a roadmap for how the agency intends to police the rapidly growing telehealth marketplace.
For months, patients and providers have debated whether FDA enforcement actions represented an effort to squeeze 503A compounding out of existence. The agency’s latest actions may suggest a different interpretation. Rather than targeting the act of compounding itself, regulators appear increasingly focused on the claims being made about compounded medications and the companies selling them.
The examples cited by FDA are revealing. The agency objects to telehealth companies marketing compounded medications as equivalent to FDA-approved products, suggesting compounded drugs themselves are FDA-approved, claiming products come from “FDA-approved” pharmacies, or presenting branding that implies a telehealth company is the actual compounder. FDA also specifically calls out claims that compounded medications have been proven to achieve the same results as their FDA-approved counterparts.
Taken together, the concerns share a common theme: consumer confusion. The agency appears less concerned with the existence of compounded GLP-1 medications than with patients potentially misunderstanding what those products are. In FDA’s view, there is a meaningful distinction between an FDA-approved drug and a compounded alternative, and the agency wants that distinction preserved in marketing materials.
That does not mean 503A pharmacies who do not follow policy and previous guidance are off the hook. Nor does it mean the broader regulatory battle over compounded GLP-1s is over. The FDA has repeatedly demonstrated its willingness to take action when it believes compounders or telehealth companies have crossed legal boundaries. But this week’s guidance provides perhaps the clearest evidence yet that the agency sees promotional claims as a primary enforcement target.
That is an important distinction for patients following every FDA action in the compounded GLP-1 space. Many interpreted previous warning letters as evidence that regulators were preparing a sweeping assault on compounding itself. The latest guidance paints a much narrower picture. FDA is signaling that its immediate concern is not simply that compounded GLP-1s exist. Its concern is how they are being marketed.
The telehealth industry grew at breakneck speed during the GLP-1 shortage era. Marketing often evolved faster than regulatory guidance, with companies competing aggressively for patients and market share. The FDA’s latest actions suggest regulators believe that some of those marketing practices have crossed the line.
Whether that line is clear enough for industry participants remains an open question. What is becoming increasingly clear, however, is where the FDA is choosing to draw it.
For now, the agency’s message appears straightforward: if you are marketing compounded GLP-1 medications, watch what you say. The latest warning letters suggest FDA views the marketing claims surrounding compounded drugs as a more immediate problem than 503A compounding itself. That may ultimately be the most important takeaway from this week’s enforcement actions.
